An open-label, randomized, parallel, phase ii trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer

A Korean Gynecologic Oncology Group Study (KGOG-3021)

Shin Wha Lee, Yong Man Kim, Chi Heum Cho, YoungTae Kim, Seok Mo Kim, Soo Young Hur, Jae-Hoon Kim, Byoung Gie Kim, Seung Cheol Kim, Hee Sug Ryu, Soon Beom Kang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose Genexol-PM is a biodegradable cremophor EL-free polymeric micelle formulation of paclitaxel. Here, we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol plus carboplatin for ovarian cancer treatment. Materials and Methods In this multicenter, randomized, phase II study, patients with International Federation of Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 area under the curve carboplatin every 3 weeks (6 cycles). The primary endpoint was the carbohydrate antigen 125 and Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR). Results Of 131 enrolled patients, 98 were included in intention-to-treat analysis. Mean dosages were 260.00±0.00 mg/m2 Genexol-PM or 174.24±3.81 mg/m2 Genexol. Median followup was 18.0 months (range, 6.1 to 33.8 months). ORR was 88.0% (95% confidence interval [CI], 80.4 to 95.6) with Genexol-PM, and 77.1% (95% CI, 67.1 to 87.1) with Genexol (noninferiority threshold, 16.3%). Median time to progression was 14.8 months (95% CI, 11.3 to 20.2) with Genexol-PM and 15.4 months (95% CI, 13.2 to 29.6) with Genexol (p=0.550). Overall, six patients died. Neutropenia was the most common toxicity (incidences of 86.0% vs. 77.1%, p=0.120). Peripheral neuropathy incidences were 84.0% versus 64.6% (p= 0.148). Peripheral neuropathy of ! grade 3 occurred in one patient receiving Genexol. All toxicities were manageable. Conclusion Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard paclitaxel regimen. Further studies are warranted to optimize the dose and schedule, and to investigate long-term outcomes.

Original languageEnglish
Pages (from-to)195-203
Number of pages9
JournalCancer Research and Treatment
Volume50
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Micelles
Paclitaxel
Ovarian Neoplasms
Carboplatin
Safety
Confidence Intervals
Peripheral Nervous System Diseases
Therapeutics
Intention to Treat Analysis
Incidence
Neutropenia
Gynecology
Obstetrics
Area Under Curve
Appointments and Schedules
Carbohydrates
cremophor
Antigens
Ovarian epithelial cancer

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{5b58106b6a85449f93eec27921e6c956,
title = "An open-label, randomized, parallel, phase ii trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)",
abstract = "Purpose Genexol-PM is a biodegradable cremophor EL-free polymeric micelle formulation of paclitaxel. Here, we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol plus carboplatin for ovarian cancer treatment. Materials and Methods In this multicenter, randomized, phase II study, patients with International Federation of Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 area under the curve carboplatin every 3 weeks (6 cycles). The primary endpoint was the carbohydrate antigen 125 and Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR). Results Of 131 enrolled patients, 98 were included in intention-to-treat analysis. Mean dosages were 260.00±0.00 mg/m2 Genexol-PM or 174.24±3.81 mg/m2 Genexol. Median followup was 18.0 months (range, 6.1 to 33.8 months). ORR was 88.0{\%} (95{\%} confidence interval [CI], 80.4 to 95.6) with Genexol-PM, and 77.1{\%} (95{\%} CI, 67.1 to 87.1) with Genexol (noninferiority threshold, 16.3{\%}). Median time to progression was 14.8 months (95{\%} CI, 11.3 to 20.2) with Genexol-PM and 15.4 months (95{\%} CI, 13.2 to 29.6) with Genexol (p=0.550). Overall, six patients died. Neutropenia was the most common toxicity (incidences of 86.0{\%} vs. 77.1{\%}, p=0.120). Peripheral neuropathy incidences were 84.0{\%} versus 64.6{\%} (p= 0.148). Peripheral neuropathy of ! grade 3 occurred in one patient receiving Genexol. All toxicities were manageable. Conclusion Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard paclitaxel regimen. Further studies are warranted to optimize the dose and schedule, and to investigate long-term outcomes.",
author = "Lee, {Shin Wha} and Kim, {Yong Man} and Cho, {Chi Heum} and YoungTae Kim and Kim, {Seok Mo} and Hur, {Soo Young} and Jae-Hoon Kim and Kim, {Byoung Gie} and Kim, {Seung Cheol} and Ryu, {Hee Sug} and Kang, {Soon Beom}",
year = "2018",
month = "1",
day = "1",
doi = "10.4143/crt.2016.376",
language = "English",
volume = "50",
pages = "195--203",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "1",

}

An open-label, randomized, parallel, phase ii trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer : A Korean Gynecologic Oncology Group Study (KGOG-3021). / Lee, Shin Wha; Kim, Yong Man; Cho, Chi Heum; Kim, YoungTae; Kim, Seok Mo; Hur, Soo Young; Kim, Jae-Hoon; Kim, Byoung Gie; Kim, Seung Cheol; Ryu, Hee Sug; Kang, Soon Beom.

In: Cancer Research and Treatment, Vol. 50, No. 1, 01.01.2018, p. 195-203.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An open-label, randomized, parallel, phase ii trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer

T2 - A Korean Gynecologic Oncology Group Study (KGOG-3021)

AU - Lee, Shin Wha

AU - Kim, Yong Man

AU - Cho, Chi Heum

AU - Kim, YoungTae

AU - Kim, Seok Mo

AU - Hur, Soo Young

AU - Kim, Jae-Hoon

AU - Kim, Byoung Gie

AU - Kim, Seung Cheol

AU - Ryu, Hee Sug

AU - Kang, Soon Beom

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose Genexol-PM is a biodegradable cremophor EL-free polymeric micelle formulation of paclitaxel. Here, we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol plus carboplatin for ovarian cancer treatment. Materials and Methods In this multicenter, randomized, phase II study, patients with International Federation of Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 area under the curve carboplatin every 3 weeks (6 cycles). The primary endpoint was the carbohydrate antigen 125 and Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR). Results Of 131 enrolled patients, 98 were included in intention-to-treat analysis. Mean dosages were 260.00±0.00 mg/m2 Genexol-PM or 174.24±3.81 mg/m2 Genexol. Median followup was 18.0 months (range, 6.1 to 33.8 months). ORR was 88.0% (95% confidence interval [CI], 80.4 to 95.6) with Genexol-PM, and 77.1% (95% CI, 67.1 to 87.1) with Genexol (noninferiority threshold, 16.3%). Median time to progression was 14.8 months (95% CI, 11.3 to 20.2) with Genexol-PM and 15.4 months (95% CI, 13.2 to 29.6) with Genexol (p=0.550). Overall, six patients died. Neutropenia was the most common toxicity (incidences of 86.0% vs. 77.1%, p=0.120). Peripheral neuropathy incidences were 84.0% versus 64.6% (p= 0.148). Peripheral neuropathy of ! grade 3 occurred in one patient receiving Genexol. All toxicities were manageable. Conclusion Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard paclitaxel regimen. Further studies are warranted to optimize the dose and schedule, and to investigate long-term outcomes.

AB - Purpose Genexol-PM is a biodegradable cremophor EL-free polymeric micelle formulation of paclitaxel. Here, we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol plus carboplatin for ovarian cancer treatment. Materials and Methods In this multicenter, randomized, phase II study, patients with International Federation of Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 area under the curve carboplatin every 3 weeks (6 cycles). The primary endpoint was the carbohydrate antigen 125 and Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR). Results Of 131 enrolled patients, 98 were included in intention-to-treat analysis. Mean dosages were 260.00±0.00 mg/m2 Genexol-PM or 174.24±3.81 mg/m2 Genexol. Median followup was 18.0 months (range, 6.1 to 33.8 months). ORR was 88.0% (95% confidence interval [CI], 80.4 to 95.6) with Genexol-PM, and 77.1% (95% CI, 67.1 to 87.1) with Genexol (noninferiority threshold, 16.3%). Median time to progression was 14.8 months (95% CI, 11.3 to 20.2) with Genexol-PM and 15.4 months (95% CI, 13.2 to 29.6) with Genexol (p=0.550). Overall, six patients died. Neutropenia was the most common toxicity (incidences of 86.0% vs. 77.1%, p=0.120). Peripheral neuropathy incidences were 84.0% versus 64.6% (p= 0.148). Peripheral neuropathy of ! grade 3 occurred in one patient receiving Genexol. All toxicities were manageable. Conclusion Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard paclitaxel regimen. Further studies are warranted to optimize the dose and schedule, and to investigate long-term outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85040454824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040454824&partnerID=8YFLogxK

U2 - 10.4143/crt.2016.376

DO - 10.4143/crt.2016.376

M3 - Article

VL - 50

SP - 195

EP - 203

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 1

ER -